Loading
companiesCompany
Nippon Kayaku
Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.
Also called: Nippon Kayaku Co., Ltd.日本化薬
Overview
Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Tokyo, JP
Scorecard
All companies#91of 1244 companies, score 53
- approved products +6
- targets +4
- modalities +4
- regions +7
- 24-month regulatory events +2
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 2 targets, 1,253 registry studies. Formula on the scorecards page.
Type
Stage
Public
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
EstablishedAnthracycline (topoisomerase II inhibitor), intravenous or intravesical
Pirarubicin is a doxorubicin relative developed in Japan and used there and in China for breast cancer, lymphoma, bladder cancer and other tumours, including instillation into the bladder after tumour resection.
Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
fronts
drugs
EstablishedAnthracycline (topoisomerase II inhibitor), intravenous or intravesical
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)